BCRX BIOCRYST PHARMACEUTICALS INC

BCRX financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 882796 Exchange: Nasdaq SIC: 2836 (Biological Products, (No Diagnostic Substances)) Latest filing: 10-Q filed Nov 4, 2026 Data checked: Nov 10, 2026
Showing 3 of 17 annual and 0 of 65 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Large accelerated filer
Entity Type
Operating
Public Float
$1.86B (Jun 2025)
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
DE
Fiscal Year End
December (1231)
Phone
919-859-1302
EIN
621413174
Headquarters
DURHAM, NC, 27703
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$961.51M
Net Income
$-359.66M
Total Assets
$591.07M
Total Equity
$-397.38M
Total Debt
-
Free Cash Flow
$365.85M
Ratios
Gross Margin
97.9%
Operating Margin
-30.1%
Net Margin
-37.4%
Return on Equity
90.5%
Return on Assets
-60.8%
Current Ratio
2.71x
FCF / Assets
61.9%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Fiscal 2025 results for BIOCRYST PHARMACEUTICALS INC combined $874.84M of revenue with net income of $263.86M and an operating cash inflow of $347.37M. Revenue of $874.84M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $450.71M in fiscal 2024, revenue recorded a 94.1% year-over-year increase. On a per-share basis, diluted EPS was $1.21, which connects the reported earnings outcome with the company’s diluted share count. Revenue equaled 1.7x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

The first profit layer was $855.76M of gross profit, the amount available after reported direct revenue costs to absorb operating expenses. Gross profit represented 97.8% of revenue, showing how much of the top line remained after direct costs. Operations produced $340.99M of income after the reported operating expense base, before the remaining non-operating and tax effects. The operating result equaled 39.0% of revenue, placing the absolute operating-income figure in the context of the company’s sales base. The bottom-line result was net income of $263.86M, after the operating, financing, tax, and other items recognized for the period. Net margin was 30.2%, meaning that this portion of revenue remained as net income after all recognized expenses. Pretax income was $267.39M, isolating the reported earnings outcome before the income-tax provision recognized for the fiscal year. The pretax margin was 30.6%, relating income before taxes directly to revenue. The reported income-tax provision was $3.53M, the amount recognized between pretax income and the final net-income result. The effective relationship between income tax and positive pretax income was 1.3%, without assuming a statutory-rate comparison.

Liquidity and Capital Structure

Total assets were $514.16M, supported by $633.31M of liabilities and -$119.15M of shareholder equity. The company reported negative equity of -$119.15M, a capital deficit that reduces its ability to absorb losses through book equity. At period end, current assets of $404.35M compared with current liabilities of $196.07M, defining the company’s short-term resource position. At 2.06x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Cash and equivalents totaled $89.74M, identifying the most liquid reported component available within the broader current-asset balance. The cash balance equaled 45.8% of current liabilities, showing how much near-term coverage came from cash alone. Total debt was $0.00, establishing the amount of borrowing carried within the company’s capital structure. Relative to total assets, debt measured 0.0%, showing how much of the asset base was matched by borrowing. The liabilities-to-assets relationship was 123.2%, placing reported obligations against the full positive asset balance. Cash and equivalents equaled 17.5% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 4.8% higher than fiscal 2024 assets of $490.42M, measuring the company’s own balance-sheet change.

Cash Flow and Earnings Quality

The company reported $347.37M of operating cash flow, a cash inflow that shows the cash generated by operations. The operating-cash-flow-to-net-income relationship was 1.32x, comparing cash generated by operations with the bottom-line earnings result. Capital expenditures used $2.47M, identifying the reported investment outflow deducted from operating cash flow in the free-cash-flow calculation. Capital spending absorbed 0.7% of operating cash flow, quantifying the share of cash from operations directed to investment. Free cash flow came to $344.90M, leaving a positive amount after capital expenditures. Relative to revenue, free cash flow equaled 39.4%, showing how much sales converted into cash after investment. Measured against total assets, free cash flow represented 67.1%, showing the cash productivity of the company’s assets.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for BIOCRYST PHARMACEUTICALS INC
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $874.84M $450.71M $331.41M
Cost of Revenue $19.08M $12.27M $4.48M
Gross Profit $855.76M $438.44M $326.93M
OPERATING EXPENSES
R&D Expense $166.13M $174.64M $216.57M
SG&A Expense $348.65M $266.35M $214.07M
Other Operating Expenses (derived) $0 $0 $0
Operating Income $340.99M $-2.54M $-103.71M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $108.24M
Other Income/Expense $-73.60M $-84.41M $-122.52M
Pretax Income $267.39M $-86.95M $-226.23M
Income Tax $3.53M $1.93M $310.00K
Net Income $263.86M $-88.88M $-226.54M
PER SHARE & SUPPLEMENTAL
Diluted EPS $1.21 $-0.43 $-1.18
Diluted Shares 218.58M 206.70M 192.20M
EBITDA $342.38M $-1.30M $-102.05M
Depreciation & Amortization $1.39M $1.25M $1.66M
Balance Sheet
ASSETS
Cash & Equivalents $89.74M $104.71M $110.64M
Short-term Investments $185.01M $216.14M $278.34M
Accounts Receivable $106.82M $79.07M $56.95M
Inventory $5.40M $8.09M $28.68M
Other Current Assets $17.18M $13.75M $19.54M
Current Assets $404.35M $421.97M $495.97M
PP&E (Net) $8.78M $7.78M $7.91M
Other Noncurrent Assets $5.67M $5.16M $13.08M
Noncurrent Assets $109.81M $68.45M $20.99M
Total Assets $514.16M $490.42M $516.96M
LIABILITIES
Accounts Payable $15.83M $11.64M $20.89M
Other Current Liabilities $2.42M $1.28M $7.65M
Current Liabilities $196.07M $160.38M $149.99M
Long-term Debt $0 $314.87M $303.23M
Other Noncurrent Liabilities (derived) $437.25M $491.10M $519.27M
Noncurrent Liabilities $437.25M $805.97M $822.50M
Total Liabilities $633.31M $966.35M $972.49M
EQUITY
Common Stock $2.13M $2.09M $2.06M
Additional Paid-in Capital $1.38B $1.29B $1.22B
Retained Earnings $-1.51B $-1.77B $-1.68B
Accumulated OCI $38.00K $921.00K $1.34M
Total Equity $-119.15M $-475.93M $-455.53M
Total Liabilities & Equity $514.16M $490.42M $516.96M
SUPPLEMENTAL
Shares Outstanding 213.06M 208.54M 205.77M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $347.37M $-52.02M $-95.14M
Capital Expenditures $2.47M $1.12M $2.17M
Cash from Investing $-13.69M $52.59M $-131.50M
Cash from Financing $-349.93M $-5.76M $32.49M
Free Cash Flow $344.90M $-53.14M $-97.31M
Beginning Cash (CFS) $106.32M $112.45M $306.24M
Net Change in Cash $-16.26M $-5.19M $-194.15M
Effect of FX on Cash $1.27M $-936.00K $362.00K
Calculated Ending Cash $91.34M $106.32M $112.45M
Cash per BS $89.74M $104.71M $110.64M
Cash scope difference (CFS − BS) $1.60M $1.61M $1.80M
Cash per CFS $91.34M $106.32M $112.45M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is BIOCRYST PHARMACEUTICALS INC's annual revenue?

BIOCRYST PHARMACEUTICALS INC reported $961.51M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is BIOCRYST PHARMACEUTICALS INC profitable?

No. BIOCRYST PHARMACEUTICALS INC reported $-359.66M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does BIOCRYST PHARMACEUTICALS INC generate free cash flow?

Yes. Free cash flow was $365.85M for trailing twelve months. Operating cash flow was $367.49M.